Research Spotlight: Highlights from the ASCO Annual Meeting and Beyond
Jun 24, 2026 - By Anna Berkenblit, MD, MMSc Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit , PanCAN’s Chief Scientific and Medical Officer. Each month, Dr…
Read the full articleYou might also wanna read
Did ASCO 2026 Deliver on Its Biggest Pre-Meeting Predictions?
Early results showing significant improvements in OS and progression-free survival [PFS] vs standard chemotherapy suggest that direct RAS ta
Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM
Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊
Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds
An experimental pill helped people with one of the most deadly cancers in the world live longer, researchers reported this weekend.
fox26houston.com·1mo ago
Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
npr.org·1mo ago
Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
chicagotribune.com·1mo agoExperimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial
A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre
chicagotribune.com·1mo ago
Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial
Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.
cnbc.com·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.